ProMIS Neurosciences Inc. financial data

Symbol
PMN on Nasdaq
Industry
Pharmaceutical Preparations
Location
Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada
State of incorporation
Canada (Federal Level)
Fiscal year end
December 31
Former names
AMORFIX LIFE SCIENCES LTD (to 11/3/2014)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 453 % +345%
Debt-to-equity 124 %
Return On Equity 51.6 % -95.9%
Return On Assets 23 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.7M shares +72.4%
Common Stock, Shares, Outstanding 32.7M shares +73.1%
Entity Public Float 29.7M USD
Weighted Average Number of Shares Outstanding, Basic 25.9M shares +111%
Weighted Average Number of Shares Outstanding, Diluted 26.5M shares +115%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10.6M USD +34.9%
General and Administrative Expense 6.19M USD -2.98%
Operating Income (Loss) -16.8M USD -18%
Nonoperating Income (Expense) 19.6M USD +1767%
Net Income (Loss) Attributable to Parent 2.78M USD +93.3%
Earnings Per Share, Basic 0.11 USD/shares
Earnings Per Share, Diluted 0.11 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.3M USD +5.5%
Assets, Current 18.9M USD +38.9%
Intangible Assets, Net (Excluding Goodwill) 18K USD -17.1%
Assets 18.9M USD +38.9%
Accounts Payable, Current 1.74M USD -77.8%
Accrued Liabilities, Current 481K USD -68.1%
Liabilities, Current 2.22M USD -76.3%
Liabilities 2.42M USD -75.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -371K USD 0%
Retained Earnings (Accumulated Deficit) -90.7M USD +2.97%
Stockholders' Equity Attributable to Parent 16.5M USD +339%
Liabilities and Equity 18.9M USD +38.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.3M USD -302%
Net Cash Provided by (Used in) Financing Activities 190K USD
Common Stock, Shares, Issued 32.7M shares +73.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.1M USD -297%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.3M USD +5.5%
Deferred Tax Assets, Valuation Allowance 31.9M USD +15%
Deferred Tax Assets, Gross 31.9M USD +15%
Depreciation 4.69K USD -81.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2.78M USD +93%
Deferred Tax Assets, Operating Loss Carryforwards 24.9M USD +17.5%
Preferred Stock, Shares Issued 0 shares -100%
Preferred Stock, Shares Authorized 70M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 108M USD +10.2%
Preferred Stock, Shares Outstanding 0 shares -100%
Amortization of Intangible Assets 4.99K USD -6.38%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 826K USD +204%
Interest Expense 76.8K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares